Connecting via Winsock to STN

Welcome to STN International! Enter x:x

* * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:36:08 ON 30 JUL 2008

=> file reg

=>
Uploading C:\Program Files\Stnexp\Queries\10522058.str





chain nodes :
17 18 19 20 21
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
chain bonds :
11-19 12-20 15-17 15-21 16-18
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 11-12 11-16 12-13 13-14
14-15 15-16
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 11-12 11-16 11-19 12-13 12-20 13-14 14-15 15-16
15-17 15-21 16-18

```
normalized bonds :
5-6  5-7  6-10  7-8  8-9  9-10
isolated ring systems :
containing 1 : 11 :


G1:C,N

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:Atom  12:Atom  13:Atom  14:Atom  15:Atom  16:Atom  17:CLASS  18:CLASS  19:CLASS
20:CLASS  21:CLASS



L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1                STR
```






```
G1 C,N


Structure attributes must be viewed using STN Express query preparation.


=> s l1 sam
FULL FILE PROJECTIONS:  ONLINE   **COMPLETE**
                        BATCH    **COMPLETE**
PROJECTED ITERATIONS:       114159 TO   123401
PROJECTED ANSWERS:               0 TO        0

L2            0 SEA SSS SAM L1
```

=> s l1 full

L3 18 SEA SSS FUL L1

=> d scan

L3 18 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Cyclohexene-1-carboxamide, 4-[[(2,3-dihydro-1,4-dioxino[2,3-c]pyridin-7-yl)methyl]amino]-N-(5-fluoro-6-methoxy-4-quinolinyl)-1-hydroxy-, (1R,4S)-rel-
MF C25 H25 F N4 O5

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):end

=> file ca

=> s l3
L4 1 L3

=> d ibib abs fhitstr

L4 ANSWER 1 OF 1 CA COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 140:199210 CA
TITLE: Preparation of aminocyclohexene-substituted quinolines and their azaisosteric analogues with antibacterial activity
INVENTOR(S): Davies, David Thomas; Elder, John Stephen; Forrest, Andrew Keith; Jarvest, Richard Lewis; Pearson, Neil David; Sheppard, Robert John
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004014361	A1	20040219	WO 2003-EP8153	20030723
WO 2004014361	A9	20040408		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003251474	A1	20040225	AU 2003-251474	20030723
EP 1539133	A1	20050615	EP 2003-784064	20030723
EP 1539133	B1	20060823		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

JP 2005538125	T	20051215	JP 2004-526773	20030723
AT 336995	T	20060915	AT 2003-784064	20030723
ES 2270142	T3	20070401	ES 2003-784064	20030723
US 20060040925	A1	20060223	US 2005-522058	20050714

PRIORITY APPLN. INFO.:		GB 2002-17294	A 20020725
		WO 2003-EP8153	W 20030723

OTHER SOURCE(S): MARPAT 140:199210

GI



I



II

AB Title compds. I [one of Z1-5 = N, one = CR1a and the remainder are CH, etc.; R1-1a = H, OH, (un)substituted alkoxy, etc.; R2 = H, (un)substituted-alkyl, -alkenyl; R3 = OH, alkoxy, alkenyloxy, etc.; R4 = alkyl, hydroxyalkyl, alkoxyalkyl, heterocycle, etc.; n = 0-1; AB = amido, carboxamido, acyl, etc.] and there pharmaceutically acceptable salts are prepd and disclosed as antibacterial agents. For instance, 4-amino-1-hydroxycyclohex-2-enecarboxylic acid N-(6-

methoxy[1,5]naphthyridin-4-yl)amide (preparation given) is reductively alkylated with 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxaldehyde to give II. II possessed an MIC of ≤ 2 μg/mL against S epidermidis CL7, S. aureus WCUH29, S. pneumoniae 1629, S. pyogenes CN10, H. influenzae ATCC 49247, E. faecalis 2, M. catarrhalis Ravasio, and E. coli 7623.

IT 661462-91-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aminocyclohexene-substituted quinolines and their azaisosteric analogs with antibacterial activity)

RN 661462-91-5 CA

CN 2-Cyclohexene-1-carboxamide, 4-[[(3,4-dihydro-3-oxo-2H-pyrido[3,2-b]-1,4-thiazin-6-yl)methyl]amino]-1-hydroxy-N-(6-methoxy-1,5-naphthyridin-4-yl)-, (1R,4S)-rel- (CA INDEX NAME)

Relative stereochemistry.



```
=> file marpat

=> s l1 full
FULL SEARCH INITIATED 11:37:06 FILE 'MARPAT'
FULL SCREEN SEARCH COMPLETED -    38348 TO ITERATE

 98.9% PROCESSED    37912 ITERATIONS                                 3 ANSWERS

100.0% PROCESSED    38348 ITERATIONS                                 3 ANSWERS
SEARCH TIME: 00.00.24

L5            3 SEA SSS FUL L1

=> d ibib abs fqhit l-3

L5   ANSWER 1 OF 3  MARPAT  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:         146:100974  MARPAT
TITLE:                    Preparation of cyclitol glycosaminoglycan mimetics as
                          antiviral agents
INVENTOR(S):              Banwell, Martin Gerhardt; Bonnet, Muriel; Ferro, Vito;
                          Kreipl, Andreas Th.; Renner, Jens; Offermann, Daniel
                          Andrew
PATENT ASSIGNEE(S):       Progen Industries Limited, Australia; The Australian
                          National University
```

SOURCE: PCT Int. Appl., 105pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006135973	A1	20061228	WO 2006-AU871	20060621

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: AU 2005-903280 20050622

GI



I



II



III

AB Cyclitol glycosaminoglycan mimetics I and II, wherein X is O, S, N, bond; Y is independently O, bond; R is H, CO2M, SO3M; wherein M is any pharmaceutically acceptable cation; both YR together, where Y is O, form a bridging acetal or ketal moiety bearing alkyl, aryl, arylalkyl; R1 is H, halo, CO2M, alkyl aryl; R2 is H, SO3M, CO2M, alkyl, aryl, arylalkyl, acyl; R3 is alkyl, aryl; R4 is H, alkyl, aryl; R3 and R4 are linked through a common alkyl, aryl, were prepared and tested in vitro as antiviral agents.

Thus, pyrrole cyclitol III was prepared as antiviral agent for the prevention or treatment in human of a disorder resulting from angiogenesis, metastasis, inflammation, coagulation, thrombosis, and/or microbial infection. Selected title compds. were tested against two types of herpes simplex virus HSV-1 and HSV-2 and as heparanase Inhibitor.

MSTR 1



G1 = 177

G6 = NH
G19 = OH
Patent location: claim 1
Note: additional ring formation also claimed
Note: substitution is restricted

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 3 MARPAT COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 140:199210 MARPAT
TITLE: Preparation of aminocyclohexene-substituted quinolines and their azaisosteric analogues with antibacterial activity
INVENTOR(S): Davies, David Thomas; Elder, John Stephen; Forrest, Andrew Keith; Jarvest, Richard Lewis; Pearson, Neil David; Sheppard, Robert John
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004014361	A1	20040219	WO 2003-EP8153	20030723
WO 2004014361	A9	20040408		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003251474	A1	20040225	AU 2003-251474	20030723	
EP 1539133	A1	20050615	EP 2003-784064	20030723	
EP 1539133	B1	20060823			

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

JP 2005538125	T	20051215	JP 2004-526773	20030723
AT 336995	T	20060915	AT 2003-784064	20030723
ES 2270142	T3	20070401	ES 2003-784064	20030723
US 20060040925	A1	20060223	US 2005-522058	20050714

PRIORITY APPLN. INFO.: GB 2002-17294 20020725
WO 2003-EP8153 20030723

GI



I



II

AB Title compds. I [one of Z1-5 = N, one = CR1a and the remainder are CH, etc.; R1-1a = H, OH, (un)substituted alkoxy, etc.; R2 = H, (un)substituted-alkyl, -alkenyl; R3 = OH, alkoxy, alkenyloxy, etc.; R4 = alkyl, hydroxyalkyl, alkoxyalkyl, heterocycle, etc.; n = 0-1; AB = amido, carboxamido, acyl, etc.] and there pharmaceutically acceptable salts are prepd and disclosed as antibacterial agents. For instance, 4-amino-1-hydroxycyclohex-2-enecarboxylic acid N-(6-methoxy[1,5]naphthyridin-4-yl)amide (preparation given) is reductively alkylated with 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxaldehyde to give II. II possessed an MIC of ≤ 2 μg/mL against S epidermidis CL7, S. aureus WCUH29, S. pneumoniae 1629, S. pyogenes CN10, H. influenzae ATCC 49247, E. faecalis 2, M. catarrhalis

Ravasio, and E. coli 7623.

MSTR 1

G1 = 9



G2 = 177



G13 = 88

G15 = 182-1 183-176 / 184-1 185-176



G16 = bond
G19 = O
G24 = NH
G42 = 200



Patent location: claim 1
Note: also incorporates claims 13 and 14
Note: additional derivatization also claimed
Note: substitution is restricted

L5 ANSWER 3 OF 3 MARPAT COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 125:114325 MARPAT
TITLE: Aryloxycycloalkenyl and aryloxyiminocycloalkenylhydrox

yureas as 5-lipoxygenase inhibitors
INVENTOR(S): Kawai, Akiyoshi; Kawai, Makoto; Stevens, Rodney W.
PATENT ASSIGNEE(S): Pfizer Pharmaceuticals Inc., Japan; Pfizer Inc.
SOURCE: PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9615106	A1	19960523	WO 1995-IB399	19950526
W: CA, FI, JP, MX, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2205033	A1	19960523	CA 1995-2205033	19950526
CA 2205033	C	20011211		
EP 790981	A1	19970827	EP 1995-918112	19950526
EP 790981	B1	19990908		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
AT 184272	T	19990915	AT 1995-918112	19950526
ES 2135066	T3	19991016	ES 1995-918112	19950526
IN 1995DE01959	A	20050311	IN 1995-DE1959	19951025
IL 115853	A	19990817	IL 1995-115853	19951102
NO 9504530	A	19960513	NO 1995-4530	19951109
AU 9537764	A	19960516	AU 1995-37764	19951109
AU 690354	B2	19980423		
ZA 9509512	A	19970509	ZA 1995-9512	19951109
BR 9505130	A	19970909	BR 1995-5130	19951109
CZ 282832	B6	19971015	CZ 1995-2942	19951109
RU 2119479	C1	19980927	RU 1995-119414	19951109
KR 182321	B1	19990515	KR 1995-40425	19951109
PL 179023	B1	20000731	PL 1995-311325	19951109
FI 9701994	A	19970509	FI 1997-1994	19970509
FI 113643	B1	20040531		
GR 3031378	T3	20000131	GR 1999-402472	19990929
PRIORITY APPLN. INFO.:			WO 1994-JP1897	19941110
			WO 1995-IB399	19950526

OTHER SOURCE(S): CASREACT 125:114325
GI



I

AB The present invention provides preparation of title compds. I [Ar = Ph, naphthyl, biphenyl, each optionally substituted with C1-4 alkyl, C1-4 haloalkyl, C1-4 hydroxyalkyl, C1-4 alkoxy, C1-4 haloalkoxy, C2-4 alkoxyalkoxy, C1-4 alkylthio, hydroxy, halo, cyano, amino, C1-4 alkylamino, di(C2-8)alkylamino, C2-6 alkanoylamino, carboxy, C2-6

alkoxycarbonyl, or optionally substituted Ph, phenoxy, phenylthio or phenylsulfinyl; furyl, benzo[b]furyl, thienyl, benzo[b]thienyl, pyridyl, quinolyl, each optionally substituted with C1-4 alkyl, C1-4 haloalkyl, halo, C1-4 alkoxy, optionally-substituted Ph, phenoxy or phenylthio, X = C1-C4 alkylene, C2-C4 alkenylene, -(CHR1)m-Q1-(CHR2)n-, -O-(CHR1)jQ2- and -(CHR1)-O-N; N moiety is attached to the cycloalkene ring; Q1 = O, S, SO, SO2, NR3, CH:N-O, CO; Q2 = O, S, SO, SO2, NR3; R1, R2, R3 = H, C1-C4 alkyl; m, n = 0-4; j = 1-4; p = 1, 2; Y = H, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, C2-4 alkoxyalkyl, C1-4 alkylthio, hydroxy, halo, cyano, amino; Z = H, C1-4 alkyl; M = H, a pharmaceutically acceptable cation or a pharmaceutically acceptable metabolically cleavable group]. Further the invention provides a pharmaceutical composition for treating a medical condition for which a 5-lipoxygenase inhibitor is needed in a mammalian subject which comprises a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. Preferably the medical condition is an inflammatory disease, allergy or cardiovascular diseases. Thus, deprotection of N,O-bis(tert-butoxycarbonyl)-N-{(1R,4R)-trans-4-(4-fluorophenoxy)-2-cyclopentyl-1-yl}hydroxylamine (preparation given) with TFA gave hydroxylamine which on treatment with Me3SiNCO in THF gave title compound, N-{(1R,4R)-trans-4-(4-fluorophenoxy)-2-cyclopenten-1-yl}-N-hydroxyurea.

MSTR 1



G1 = quinolinyl (opt. substd.)
G8 = 10-1 11-3

G9 = 38-10 41-3



G12 = 120-1 121-11

G16 = O
Patent location: claim 1

```
Note:                          substitution is restricted


=> d his

     (FILE 'HOME' ENTERED AT 11:36:08 ON 30 JUL 2008)

     FILE 'REGISTRY' ENTERED AT 11:36:22 ON 30 JUL 2008
L1             STRUCTURE UPLOADED
L2               0 S L1 SAM
L3              18 S L1 FULL

     FILE 'CA' ENTERED AT 11:36:48 ON 30 JUL 2008
L4               1 S L3

     FILE 'MARPAT' ENTERED AT 11:37:03 ON 30 JUL 2008
L5               3 S L1 FULL

=>

---Logging off of STN---


=>
Executing the logoff script...

=> LOG Y

STN INTERNATIONAL LOGOFF AT 11:37:53 ON 30 JUL 2008
```